TScan Therapeutics, Inc. (TCRX) Reports In-Line Q2 EPS

TScan Therapeutics, Inc. (NASDAQ: TCRX) reported Q2 EPS of ($0.28), in-line with the analyst estimate of ($0.28). Revenue for the quarter came in at $500 thousand versus the consensus estimate of $1.8 million.

For earnings history and earnings-related data on TScan Therapeutics, Inc. (TCRX) click here.

You May Also Be Interested In

• Apogee Enterprises (APOG) Tops Q1 EPS by 16c, Beats on Revenue; Offers FY27 Guidance
• Titan Mining wins U.S. Army lease to build graphite facility on military land
• Winnebago Industries (WGO) Misses Q3 EPS by 11c ; Offers Guidance